HOUSTON, Nov. 21, 2024 /PRNewswire/ -- Autoimmunity BioSolutions (ABS), a biotechnology company pioneering a next-generation, immuno-corrective therapy for a highly prevalent, genetically-defined subpopulation of patients that suffer from autoimmune disease, announced the closing of a...
Autoimmunity BioSolutions raises $2M Series Seed to advance development of a next-generation, immuno-corrective therapy for autoimmune disease treatment
Seaking AlphaSeeking Alpha / Seaking Alpha 9 hours ago 1 Views
Comments